PDF Version

PDF版本

Icovamenib is an oral covalent menin inhibitor in clinical development to investigate its impact on the function of insulin-producing beta cellsREDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that the World Health Organization (WHO) has approved “icovamenib” as the International Nonproprietary Name (INN) for its lead product candidate BMF-219, and that the United States Adopted Name Council has adopted “icovamenib” as the United States Adopted Name (USAN) for BMF-219.

Icovamenib是临床开发中的一种口服共价menin抑制剂，为了研究其对产生胰岛素的β细胞功能的影响，加利福尼亚州德伍德市，2024年10月21日（环球新闻通讯社）--Biomea Fusion，Inc.（“Biomea”）（纳斯达克：BMEA），一家临床阶段的生物制药公司，致力于发现和开发口服共价小分子，以治疗和改善糖尿病，肥胖症和基因定义癌症患者的生活，今天宣布，世界卫生组织（WHO）已批准“Icovamenib”作为其主要产品候选BMF-219的国际非专有名称（INN），美国采用名称委员会采用“Icovamenib”作为BMF-219的美国通用名称（USAN）。

The suffix ‘-menib’ stands for menin inhibitor. An International Nonproprietary Name (INN) is a unique, globally recognized name for a pharmaceutical drug or active ingredient. A United States Adopted Name (USAN) is a nonproprietary name selected by the USAN Council to ensure safety, consistency and logic in the choice of names of US medications; the USAN Council, is co-sponsored by the American Medical Association, the United States Pharmacopeial Convention, and the American Pharmacists Association.

后缀“-menib”代表menin抑制剂。国际非专有名称（INN）是全球公认的药物或活性成分的唯一名称。；USAN理事会由美国医学协会、美国药典公约和美国药剂师协会共同赞助。

WHO’s INN Expert Group and the USAN Council approve simple, informative and unique nonproprietary names, also known as generic names. Biomea will use “icovamenib” in upcoming presentations, publications and public statements as the company advances the clinical development of the product candidate. To learn more about icovamenib and its potential impact in diabetes please visit our website at https://biomeafusion.com/diabetes-obesity.

WHO的INN专家组和USAN理事会批准了简单、信息丰富且独特的非专有名称，也称为通用名称。随着公司推进候选产品的临床开发，Biomea将在即将到来的演示、出版物和公开声明中使用“icovamenib”。要了解更多关于埃科瓦美尼及其对糖尿病的潜在影响，请访问我们的网站https://biomeafusion.com/diabetes-obesity.

About Biomea FusionBiomea Fusion is a clinical stage biopharmaceutical company focused on the di.

关于Biomea Fusion Biomea Fusion是一家专注于di的临床阶段生物制药公司。

Investor Relations

投资者关系

Chunyi Zhao, PhD

赵，博士

Associate Director of Investor Relations & Corporate Development

czhao@biomeafusion.com

czhao@biomeafusion.com

Media Relations

媒体关系

Neera Chaudhary

尼拉·乔杜里

nchaudhary@biomeafusion.com

nchaudhary@biomeafusion.com